According to the Latest Report: Parkinson’s Disease Therapeutic Market is Expected Significant Growth by Forecast 2021 to 2027
Parkinson’s disease therapeutics has an important role to play in the lives of people with this condition who are affected by this debilitating disease. This is because the medicines developed for this condition can be very effective in the cure of this condition and at the same time prevent it from recurring. Parkinson’s disease is a disorder of the central nervous system which results in involuntary movements of the body. This includes the difficulty in holding, maintaining, and moving certain body functions such as swallowing, walking, swallowing, and talking. The development of Parkinson’s disease occurs in the later stages of life and this means that there are fewer and less effective drugs available in the current market for treating the condition.
Request Here For PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/494
Key Market Drivers:
The increasing cases of Parkinson’s disease in the world are the main factor that is expected to augment the growth of the global Parkinson’s disease therapeutics market. For instance, according to Parkinson’s Foundation, over 10 million individuals in the world are suffering from Parkinson’s disease (PD). The incidence of PD increases with increasing age, however, an expected 4% of individuals with this disease are diagnosed before 50 years of age. Currently, the most commonly used Parkinson’s disease therapeutics include the tricyclic antidepressants clomipramine and troglitazone acetaminophen. These drugs have been used for the treatment of mild to moderate cases of the disease and the mechanism of action is the inhibition of dopamine transporters in the brain. A newer drug, leupeptin, which acts on neuro endorphins and ionizing neurochemicals, has also shown some success as a nonmotor symptom reducer. Hence, the increasing launch of new treatment methods by key market players is estimated to fuel the growth of the global Parkinson’s disease therapeutics market.
Covid-19 Impact Analysis:
During the high peak of the COVID-19 pandemic, the healthcare sector faced a lot of challenges owing to increasing requirements for healthcare attentions. Moreover, the COVID-19 had a more negative effect on the patients with PD. For instance, according to Medical News, a recent study has found that PD patients, who are tested positive with the COVID-19 experienced worse motor symptoms after the infection. These symptoms include severe spasms in all limbs, dementia, delirium, tremors, altered gait, and bradykinesia.
The size of the global Parkinson’s disease therapeutics market is expected to increase at a CAGR of 6.1% to reach around US$ 5.69 billion in 2022, owing to the increasing incidence of Parkinson’s disease in the world, along with launches by key market players. For instance, in August 2019, U.S. Food and Drug Administration approved NOURIANZ (istradefylline), developed by Kyowa Kirin Co., Ltd.
North America is expected to hold a major share of the global Parkinson’s disease therapeutics market, owing to the increasing prevalence of PD in the region. For instance, according to Parkinson’s Foundation, around 1 million individuals in the U.S. are suffering from PD.
Europe is estimated to witness high growth in the global Parkinson’s disease therapeutics market, owing to the increasing strategies by key market players for expansion in the European market. For instance, in December 2018, the distribution and sales of Stalevo, a Parkinson’s disease drug in some European nations was acquired by Orion Corporation.
Major Key Players Include In Parkinson’s Disease Therapeutic Market: Salix Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., Mylan N.V., Orion Corporation, Boehringer Ingelheim, UCB, and Impax Labs.
Main points in Parkinson’s Disease Therapeutic Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Parkinson’s Disease Therapeutic Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Parkinson’s Disease Therapeutic Industry Impact
Chapter 2 Global Parkinson’s Disease Therapeutic Competition by Types, Applications, and Top Regions and Countries
2.1 Global Parkinson’s Disease Therapeutic (Volume and Value) by Type
2.3 Global Parkinson’s Disease Therapeutic (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Parkinson’s Disease Therapeutic Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Parkinson’s Disease Therapeutic Market Analysis
Chapter 6 East Asia Parkinson’s Disease Therapeutic Market Analysis
Chapter 7 Europe Parkinson’s Disease Therapeutic Market Analysis
Chapter 8 South Asia Parkinson’s Disease Therapeutic Market Analysis
Chapter 9 Southeast Asia Parkinson’s Disease Therapeutic Market Analysis
Chapter 10 Middle East Parkinson’s Disease Therapeutic Market Analysis
Chapter 11 Africa Parkinson’s Disease Therapeutic Market Analysis
Chapter 12 Oceania Parkinson’s Disease Therapeutic Market Analysis
Chapter 13 South America Parkinson’s Disease Therapeutic Market Analysis
Chapter 14 Company Profiles and Key Figures in Parkinson’s Disease Therapeutic Business
Chapter 15 Global Parkinson’s Disease Therapeutic Market Forecast (2021-2027)
Chapter 16 Conclusions
Buy instant copy of this research report with Flat US $ 2000 Off@ https://www.coherentmarketinsights.com/promo/buynow/494
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
- CDN Newswire